Within Alberta, the real-world data analysis of MYL-1401O use in early-stage HER2-positive breast cancer demonstrates similar pathological response rates as TRZ, thus justifying its use within our public health system as an excellent cost-effective alternative to trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.